Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (291-300 of 868) with videos related to

Pageof 87
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.
Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.
Oncotarget|August 26, 2021
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.
Blood|May 14, 2010
Kidney disease associated with plasma cell dyscrasiasEliot C Heher, Nelson B Goes, Thomas R Spitzer, et al.
Hematology/Oncology Clinics of North America|November 13, 2007
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapiesConstantine S Mitsiades, Douglas W McMillin, Steffen Klippel, et al.
Molecular Cancer Therapeutics|December 21, 2002
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation studyPaul G Richardson, Asher A Chanan-Khan, Melissa Alsina, et al.
Pageof 87

Showing results (291-300 of 868) with videos related to

Sort By:
Pageof 87
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.
Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.
Oncotarget|August 26, 2021
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.
Blood|May 14, 2010
Kidney disease associated with plasma cell dyscrasiasEliot C Heher, Nelson B Goes, Thomas R Spitzer, et al.
Hematology/Oncology Clinics of North America|November 13, 2007
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapiesConstantine S Mitsiades, Douglas W McMillin, Steffen Klippel, et al.
Molecular Cancer Therapeutics|December 21, 2002
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation studyPaul G Richardson, Asher A Chanan-Khan, Melissa Alsina, et al.
Pageof 87